Get the Stockscreener App
24.61
3.49%
0.83
Celldex Therapeutics Inc stock is traded at $24.61, with a volume of 861.21K.
It is up +3.49% in the last 24 hours and down -2.11% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
See More
Previous Close:
$23.78
Open:
$23.95
24h Volume:
861.21K
Relative Volume:
0.90
Market Cap:
$1.63B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-9.5388
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+7.28%
1M Performance:
-2.11%
6M Performance:
-33.05%
1Y Performance:
-38.46%
1-Day Range:
$23.70
$24.91
1-Week Range:
$22.16
$24.91
52-Week Range:
$22.16
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
24.61 | 1.63B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat
Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa
Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
Guggenheim maintains $90 target on Celldex stock after study By Investing.com - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap UpHere's Why - MarketBeat
Before You Invest, Make Sure You Check This Asset Entities Inc (NASDAQ: ASST) Analysis - Stocks Register
What Do Wall Street Analysts Think About Celldex Therapeutics Inc (NASDAQ: CLDX) Stock? - Stocks Register
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Canada
Celldex Therapeutics’ SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com South Africa
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Drops By 5.1% - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Barclays PLC Has $4.43 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
What Analysts Are Saying About Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - The Manila Times
Celldex Launches Pivotal Phase 2 Trial for Novel Atopic Dermatitis Treatment, Targeting 20% of US Population - StockTitan
State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.5%Here's Why - MarketBeat
BNP Paribas Financial Markets Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
XTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Wellington Management Group LLP Acquires 1,167,659 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
The Manufacturers Life Insurance Company Cuts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Readystate Asset Management LP Takes $6.10 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Redmile Group LLC Cuts Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Cinctive Capital Management LP Decreases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Position Decreased by Fmr LLC - MarketBeat
Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $62.25 - MarketBeat
Prurigo Nodularis Pipeline Insights 2024: Therapies, Clinical - openPR
CBC acquires UCB’s neurology and allergy business in China - Pharmaceutical Technology
Bellevue Group AG Buys 100,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Intech Investment Management LLC Makes New $871,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Fisher Asset Management LLC Buys 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):